Obesity in children: criteria for predicting the development of hypertension

Article Sidebar

PDF (Українська)
Published: Mar 1, 2020
DOI: https://doi.org/10.22141/2224-0721.16.2.2020.201299
Keywords:
children, obesity, overweight, hypertension, prognostic criteria

Main Article Content

T.V. Sorokman
Bukovinian State Medical University, Chernivtsi, Ukraine
https://orcid.org/0000-0001-7615-3466
N.O. Popeliuk
Bukovinian State Medical University, Chernivtsi, Ukraine
https://orcid.org/0000-0003-3961-7529

Abstract

Background. Obesity in childhood causes a wide range of serious complications and increased risk of diabetes, hypertension, cardiovascular and other diseases. Formation of various types of hypertension in adolescents with overweight and obesity is cha­racterized by imbalance in the production of biologically active substances. Materials and methods. One hundred and sixty people were examined: with overweight (n = 35), obesity (abdominal (n = 35), uniform (n = 35)), and 55 healthy people. Blood lipids (total cholesterol, triglycerides, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol), endothelin-1, β2-micro­globulin were studied, as well as 6-hydroxymelatonin sulfate in the urine. Results. A significant increase in the average daily va­lues of systolic, diastolic, mean hemodynamic and pulse blood pressure was established. Obese children had a tendency to react excessively in the form of an increase in the daily rate of systolic blood pressure elevations. In 57.1 % of patients with obesity, pathological abnormalities of the blood lipids were found: levels of total cholesterol, LDL cholesterol, triglycerides were higher, and HDL cholesterol was lower in both groups of patients. A significant increase in the content of endothelin-1 and β2-microglobulin in the blood plasma of obese children and a tendency towards an increase in children with overweight, disturbances of the circadian rhythm of 6-hydroxymelatonin sulfate secretion were revealed. Conclusions. Metabolic risk factors for the development of hypertension have been identified in children with obesity and overweight: dyslipidemia (hypertriglyceridemia, increased LDL cholesterol, reduced HDL cholesterol), increased β2-microglobulin and endothelin-1 levels, and an imbalance of melatonin secretion. Patients with these adverse factors should be closely monitored by a physician. A special attention should be paid to children with overweight as potential candidates for the development of obesity and its complications, including arterial hypertension.

Article Details

How to Cite
Sorokman, T., and N. Popeliuk. “Obesity in Children: Criteria for Predicting the Development of Hypertension”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 16, no. 2, Mar. 2020, pp. 138-44, doi:10.22141/2224-0721.16.2.2020.201299.
Issue
Vol. 16 No. 2 (2020)
Section
Original Researches
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our edition uses the copyright terms of Creative Commons for open access journals.

Authors, who are published in this journal, agree with the following terms:

  1. The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
  2. Directing  the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
  3. The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
  4. The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
  5. The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
  6. The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.

References

World Health Organization (WHO). Consideration of the evidence on childhood obesity for the Commission on Ending Childhood Obesity: report of the ad hoc working group on science and evidence for ending childhood obesity. Geneva, Switzerland: WHO-press; 2016. 218 p.

NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627–2642. doi:10.1016/S0140-6736(17)32129-3.

Roberto CA, Swinburn B, Hawkes C, et al. Patchy progress on obesity prevention: emerging examples, entrenched barriers, and new thinking. Lancet. 2015;385(9985):2400–2409. doi:10.1016/S0140-6736(14)61744-X.

Lobstein T, Jackson-Leach R, Moodie ML, et al. Child and adolescent obesity: part of a bigger picture. Lancet. 2015;385(9986):2510–2520. doi:10.1016/S0140-6736(14)61746-3.

Cunningham SA, Kramer MR, Narayan KM. Incidence of childhood obesity in the United States. N Engl J Med. 2014;370(17):1660–1661. doi:10.1056/NEJMc1402397.

Dzhumagaziev AA, Bezrukova DA, Bogdanyants MV, et al. Obesity in Children in the Modern World: Realities and Possible Solutions. Voprosy sovremennoj pediatrii. 2016;15(3):250–256. doi:10.15690/vsp.v15i3.1561. (in Russian).

Dhuper S, Abdullah RA, Weichbrod L, Mahdi E, Cohen HW. Association of obesity and hypertension with left ventricular geometry and function in children and adolescents. Obesity (Silver Spring). 2011;19(1):128–133. doi:10.1038/oby.2010.134.

Senatorova AS, Chaichenko TV, Boichenko AD. Anthropometric predictors of myocardial remodeling in overweight and obese adolescents. Zdorovʹe rebenka. 2011;(35):25–29. (in Russian).

Posokhova NV. Mechanisms of arterial hypertension formation in obese children. Bulletin of Medical Internet Conferences. 2013;3(2):331. (in Russian).

Netrebenko OK. Obesity in children: the origins of problems and finding solutions. Pediatria. 2011;90(6):104–113. (in Russian).

Pavlovskaya EV, Strokova TV, Surkov AG, Bogdanov AR, Kaganov BS. Metabolic disturbances in preschool children with obesity. Rossiiskii vestnik perinatologii i pediatrii. 2013;58(6):91–97. (in Russian).

Kvashnina LV, Ignatova TB. Prophylaxis of disturbances of endothelial function within the children during transition from health to a syndrome of vegetative dysfunction. Sovremennaya pedyatriya. 2016;(77):16–24. (in Russian).

Minakova VA. Markers level of endothelial dysfunction (endotelin-1 and nitrogen oxide) in blood syrovists and albuminuria in children with erythrocyturia. Ukrainian Journal of Nephrology and Dialysis. 2017;(55):49–54. (in Ukrainian).

Shadrin SA, Statova AV. Prevalence and characteristics of lipid metabolism disorders in children from Krasnodar region of Russia. Obesity and metabolism. 2014;11(1):38–41. (in Russian).

Real de Asúa D, Puchades R, García-Polo I, Suárez C. A Study on the Relationship between Serum Beta 2-Microglobulin Levels, Underlying Chronic Kidney Disease, and Peripheral Arterial Disease in High-Vascular-Risk Patients. Int Cardiovasc Res J. 2012;6(4):107–112.

Dionne JM, Harris KC, Benoit G, et al. Hypertension Canada's 2017 Guidelines for the Diagnosis, Assessment, Prevention, and Treatment of Pediatric Hypertension. Can J Cardiol. 2017;33(5):577–585. doi:10.1016/j.cjca.2017.03.007.

Rapoport SI, Molchanov AYu, Golichenkov VA, Burlakova OV, Suprunenko ES, Savchenko ES. Metabolic syndrome and melatonin. Klinicheskaia meditsina. 2013;91(11):8–14. (in Russian).

Reiter RJ, Manchester LC, Fuentes-Broto L, Tan DX. Cardiac hypertrophy and remodelling: pathophysiological consequences and protective effects of melatonin. J Hypertens. 2010;28 Suppl 1:S7–S12. doi:10.1097/01.hjh.0000388488.51083.2b.

Ryznychuk MO, Pishak VP. Obesity: The role of desynchronosis and genetic factors in mechanisms of its development. Regulatory Mechanisms in Biosystems. 2017;8(1):23–29. doi: 10.15421/021705. (in Ukrainian).

Kaladze MM, Zyukova IB. Epiphysis implication in chronobiological features of arterial hypertension among children. Sovremennaya pedyatriya. 2014;(59):94–97. doi:10.15574/SP.2014.59.94. (in Russian).

Imenshahidi M, Karimi G, Hosseinzadeh H. Effects of melatonin on cardiovascular risk factors and metabolic syndrome: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol. 2020;393(4):521–536. doi:10.1007/s00210-020-01822-4.

Sun H, Gusdon AM, Qu S. Effects of melatonin on cardiovascular diseases: progress in the past year. Curr Opin Lipidol. 2016;27(4):408–413. doi:10.1097/MOL.0000000000000314.

Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br J Pharmacol. 2018;175(16):3190–3199. doi:10.1111/bph.14116.

Tordjman S, Chokron S, Delorme R, et al. Melatonin: Pharmacology, Functions and Therapeutic Benefits. Curr Neuropharmacol. 2017;15(3):434–443. doi:10.2174/1570159X14666161228122115.

Chaichenko TV. Optimization of physical activity among children and adolescents in the campaign to end childhood obesity. Zdorovʹe rebenka. 2015;(64):31–35. doi:10.22141/2224-0551.4.64.2015.75241. (in Russian).

Maskova GS, Chernaya NL, Shubina EV, Aleksandrova SV. The age features of primary obesity in children. Practical medicine. 2014;(85):126–130. (in Russian).

Pavlishin GA. Furdela WB, Samson OA. Just go to the diagnosis of childhood obesity. Fundamentalni doslidzhennia. 2012;(26-27):47–51. (in Ukrainian).

Zimmet P, Alberti KG, Kaufman F, et al. The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes. 2007;8(5):299–306. doi:10.1111/j.1399-5448.2007.00271.x.

McCarthy HD, Cole TJ, Fry T, Jebb SA, Prentice AM. Body fat reference curves for children. Int J Obes (Lond). 2006;30(4):598–602. doi:10.1038/sj.ijo.0803232.

Averiyanov AP, Bolotova NV, Zotova SA. Obesity obesity in childhood. Lechaschii Vrach. 2010;(2):69. (in Russian).

Strogiy VV, Abrosimowa NN, Koren IA, Sikora MP. Features of circadian blood pressure in children and adolescents with various forms of obesity. Belorusskii meditsinskii zhurnal. 2012;(39):125–129. (in Russian).

International Society for Chronobiology; American Association of Medical Chronobiology and Chronotherapeutics; Spanish Society of Applied Chronobiology, Chronotherapy, and Vascular Risk. 2013 ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals. Chronobiol Int. 2013;30(3):355–410. doi:10.3109/07420528.2013.750490.

Liu Y, Shi L, Lin Y, et al. Relationship Between Blood Pressure Variability and Target Organ Damage in Children With Essential Hypertension. Zhonghua Er Ke Za Zhi. 2019;57(2):93–97. doi:10.3760/cma.j.issn.0578-1310.2019.02.006.

Cardinali DP, Cano P, Jiménez-Ortega V, Esquifino AI. Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications. Neuroendocrinology. 2011;93(3):133–142. doi:10.1159/000324699.

Cardinali DP, Hardeland R. Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies. Neuroendocrinology. 2017;104(4):382–397. doi:10.1159/000446543.

Liu J, Clough SJ, Hutchinson AJ, Adamah-Biassi EB, Popovska-Gorevski M, Dubocovich ML. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annu Rev Pharmacol Toxicol. 2016;56:361–383. doi:10.1146/annurev-pharmtox-010814-124742.

Sychov RO. Changes in urinary excretion of beta-2-microglobulin in hypertension J Clin Exp Med Res. 2015;3(1):129-136. (in Ukrainian).

Tomlinson PA, Dalton RN, Turner C, Chantler C. Measurement of beta 2-microglobulin, retinol-binding protein, alpha 1-microglobulin and urine protein 1 in healthy children using enzyme-linked immunosorbent assay. Clin Chim Acta. 1990;192(2):99–106. doi:10.1016/0009-8981(90)90073-2.

Steubl D, Inker LA. How best to estimate glomerular filtration rate? Novel filtration markers and their application. Curr Opin Nephrol Hypertens. 2018;27(6):398–405. doi:10.1097/MNH.0000000000000444.

Most read articles by the same author(s)

1 2 3 > >>